Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiotherapy in Early-stage Favorable cHL
NCT06916416Phase 2Not yet recruiting
- Sponsor
- University of Cologne
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Progression Free Survival at 1 year. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06916416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916416.